Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine

2020 Year in Review - AML - Leukemia

The hypomethylating agents azacitidine (AZA) and decitabine (DEC) are approved in Europe for patients who are ineligible for intensive chemotherapy (IC) or hematopoietic cell transplant, but limited data are available on comparative outcomes associated with these individual agents. This study examined the efficacy and safety of AZA versus DEC in ASTRAL-1, the largest randomized trial for patients with treatment-naïve acute myeloid leukemia (TN-AML) who were not eligible for IC.

A total of 815 patients with TN-AML who were ineligible for IC were enrolled in ASTRAL-1, a global, prospective, randomized, controlled phase 3 trial. Patients were randomized 1:1 to either the DNA methyltransferase inhibitor guadecitabine (subcutaneous [SC], 60 mg/m2 on days 1-5) or a preselected treatment choice (TC) of AZA (intravenous [IV] or SC, 75 mg/m2 on days 1-7), DEC (IV, 20 mg/m2 on days 1-5), or low-dose cytarabine (SC, 20 mg twice daily on days 1-10). The co-primary end points were rates of hematologic complete response (CR) and overall survival (OS).

Of 407 patients randomized to TC, 83% (N = 338) were treated with either AZA (N = 171) or DEC (N = 167). The AZA and DEC treatment groups were well matched, with a median age of 76 years in both arms. The following baseline characteristics were observed in the AZA and DEC groups, respectively: poor performance status 2 to 3: 47.4% versus 53.9%; poor risk cytogenetics: 38% versus 33.5%; secondary AML: 38% versus 36.5%; bone marrow blasts >30%: 63.7% versus 71.3%; and presence of TP53 mutations: 12.9% versus 11.3%. The median follow-up was 25.5 months, and the median number of treatment cycles was 6 and 5 for AZA and DEC, respectively.

The CR rate was 17.5% versus 19.2% (P = .70) for AZA versus DEC, respectively, whereas the overall CR (CR + CR with incomplete platelet recovery + CR with incomplete hematologic recovery) was 22.2% versus 25.1% (P = .53) for AZA versus DEC, respectively. The median OS was 8.7 months for AZA and 8.2 months for DEC (hazard ratio, 0.97; 95% confidence interval, 0.77-1.23; log rank P = .8).

The rates of grade ≥3 adverse events (AEs; 88.9% vs 87.4%), serious AEs (81.9% vs 76.0%), and 30-day all-cause mortality (11.7% vs 7.8%) were not significantly different between AZA and DEC, respectively. Although not statistically significant, 60-day, all-cause mortality was numerically higher with AZA (20.5%) versus DEC (13.2%; P = .07).

In this large study comparing clinical outcomes with AZA and DEC for patients with TN-AML not eligible for IC, no significant differences in CR, overall CR, OS, or safety were observed.

Reference
Zeidan AM, Fenaux P, Gobbi M, et al. Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naïve Acute Myeloid Leukemia (TN-AML) Not Eligible for Intensive Chemotherapy. Presented at: 25th European Hematology Association Congress Virtual; June 11-21, 2020. Abstract S142.

Related Items
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia, Adverse Events
Effect of Concomitant Azole Antifungals on Duration of Myelosuppression in Newly Diagnosed Patients with AML Receiving Venetoclax in Combination with Cladribine and Low-Dose Cytarabine
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Leukemia
Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature
Jessie Signorelli, PharmD, BCOP, Amir T. Fathi, MD, Gabriela Hobbs, MD
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Leukemia, Adverse Events
Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients with Blood Cancer
Lisa R. Garavaglia, PharmD , Frank Casey, MD, Lesley Cottrell, PhD, Claudiu Faraon-Pogaceanu, MD, Stephan Paul, MD, Melvin Lee Wright, DO
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Original Article, Pediatric Cancer, Leukemia, Lymphoma
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD, Beth Eddy, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Original Article, Transplant, Leukemia, Myelodysplastic Syndromes, Conditioning Regimen
Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study
Lily Y. Jia, PharmD, BCOP, Jessie Signorelli, PharmD, BCOP, Samantha O. Luk, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Article, Leukemia, Oncology Pharmacy Programs
Pegaspargase-Induced Diabetic Ketoacidosis in a Patient with Acute Lymphoblastic Leukemia
Ellen Madarang, PharmD, BCOP, Leslie Gallardo, PharmD, BCPS, Terrence Bradley, MD
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Case Reports, Acute Lymphoblastic Leukemia, Leukemia, Adverse Events
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: